<DOC>
	<DOCNO>NCT01434173</DOCNO>
	<brief_summary>Moxifloxacin broad-spectrum antibacterial agent use treat common community-acquired respiratory tract infection , complicate intra-abdominal infection , pelvic inflammatory disease . In clinical development program , moxifloxacin associate hepatic adverse drug reaction . To evaluate hepatic safety profile moxifloxacin , retrospective cohort study nest case-control analysis conduct assess rate noninfectious acute liver injury among new user moxifloxacin antimicrobial prescribe similar indication , include amoxicillin , amoxicillin plus clavulanic acid , cefuroxime , clarithromycin , doxycycline , levofloxacin , telithromycin . The study implement population include HealthCore Integrated Research Database ( HIRD ) . Eligible patient adult age 18 year older continuous enrollment HIRD least 6 month first claim prescription study antimicrobial . Follow-up start date first prescription date early follow event : noninfectious acute liver injury , occurrence exclusion criterion , end study period , disenrollment database , death . Patients chronic alcoholism cirrhosis , infectious hepatitis , HIV/AIDS , pregnant woman include .</brief_summary>
	<brief_title>Risk Acute Liver Injury Users Antimicrobials</brief_title>
	<detailed_description>Study design call 'Cohort study nest case-control analysis ''</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<mesh_term>Cefuroxime axetil</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Cefuroxime</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>All person meeting follow criterion study period ( July 1 , 2001 , March 31 , 2009 ) eligible study inclusion : First insurance claim dispense one study antimicrobial study period ( `` new user '' ) Aged 18 year old old Continuous enrollment study database least 6 month prior start followup ( date first claim study antimicrobial ) Patient data define acceptable research purpose accord quality criterion HIRD Pregnant woman Patients chronic alcoholism cirrhosis Patients history acute and/or chronic infectious hepatitis HIV/AIDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Liver Diseases</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Fluoroquinolones</keyword>
	<keyword>Amoxicillin</keyword>
	<keyword>Amoxicillin-Potassium Clavulanate Combination</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Doxycycline</keyword>
	<keyword>Cefuroxime</keyword>
	<keyword>Case-Control Studies</keyword>
	<keyword>Retrospective Studies</keyword>
	<keyword>Cohort Studies</keyword>
	<keyword>Epidemiologic Research Design</keyword>
	<keyword>Epidemiologic Studies</keyword>
	<keyword>HealthCore Integrated Research Database ( non-MESH )</keyword>
	<keyword>United States</keyword>
	<keyword>Human</keyword>
	<keyword>Insurance Claim Review</keyword>
</DOC>